The Prevalence and Clinical Significance of the Centromere Protein-F-Like Immunofluorescence Staining Pattern in a Large ANA-positive Cohort
Abstract
Objective
To investigate the prevalence and clinical significance of the centromere protein-F-like (CENP-F-like) immunofluorescence staining pattern in a large patient cohort and through literature review.
Methods
We retrospectively analyzed antinuclear antibody (ANA) immunofluorescence assay results from 191274 patients at West China Hospital of Sichuan University between March 2018 and November 2020. Specific immunological markers were tested in sera with CENP-F-like patterns. Additionally, a narrative review of seven relevant studies was performed for comparison.
Results
In Southwest China, ANA positivity was found in 32.09% of patients, with the CENP-F-like pattern detected in 0.015% of all cases and 0.05% of ANA-positive individuals. The CENP-F-like pattern appeared predominantly at titers ≥ 1∶320, most often in isolation (68.97%), but also mixed with cytoplasmic speckled patterns. Patients with cancers accounted for the highest proportion (31.03%), including solid tumors and hematologic malignancies. Metastasis was observed in patients with solid tumors, while graft-versus-host disease (GVHD) occurred in those with hematologic malignancies post-transplantation. Autoimmune diseases (AIDs) were diagnosed in 20.69% of cases, all showing disease-specific autoantibodies. These findings were broadly consistent with previous reports and suggest a possible association between the CENP-F-like pattern and malignancies.
Conclusion
The CENP-F-like pattern is rare in ANA tests but may be associated with clinically important conditions, particularly cancers and AIDs. The occurrence of metastasis and GVHD in patients with this pattern highlights its potential clinical relevance, and concurrent autoantibodies may assist in diagnosing AIDs.
Keywords: Antibodies, antinuclear, Fluorescent antibody technique, indirect, Clinical relevance. Neoplasms, Autoimmune diseases
Full Text:
PDFReferences
KĄDZIELA M, FIJAŁKOWSKA A, KRASKA-GACKA M, et al. The art of interpreting antinuclear antibodies (ANAs) in everyday practice. J Clin Med, 2025, 14(15): 5322. doi: 10.3390/jcm14155322.
KUMAR N N, AHMAD DIT AI HAKIM S, GRYGIEL-GÓRNIAK B. Antinuclear antibodies in non-rheumatic diseases. Arch Immunol Ther Exp (Warsz), 2025, 73(1): 1-20. doi: 10.2478/aite-2025-0004.
ZHANG A P, CHEN J. Progress in the pathogenesis, clinical diagnosis and treatment of immune checkpoint inhibitor-related pneumonitis. Journal of Clinical Medicine in Practice, 2024, 28(6): 133-138. doi: 10. 7619/jcmp.20232951.
XU S N, JIA Z, ZHANG N. Correlation between low anti-nuclear antibody titers and pregnancy outcomes after frozen embryo transfer. Journal of Chongqing Medical University, 2024, 49(11): 1474-1478. doi: 10.13406/j.cnki.cyxb.003612.
BONROY C, VERCAMMEN M, FIERZ W, et al. Detection of antinuclear antibodies: recommendations from EFLM, EASI and ICAP. Clin Chem Lab Med, 2023, 61(7): 1167-1198. doi: 10.1515/cclm-2023-0209.
TEŠIJA KUNA A, ĐEREK L, DRVAR V, et al. Assessment of antinuclear antibodies (ANAs): National recommendations on behalf of the Croatian society of medical biochemistry and laboratory medicine. Biochem Med (Zagreb), 2021, 31(2): 020502. doi: 10.11613/BM.2021.020502.
CHAN E K L, Von MÜHLEN C A, FRITZLER M J, et al. The international consensus on ANA patterns (ICAP) in 2021-The 6th workshop and current perspectives. J Appl Lab Med, 2022, 7(1): 322-330. doi: 10.1093/jalm/jfab140.
BARNADO A, MOORE R P, DOMENICO H J, et al. Identifying antinuclear antibody positive individuals at risk for developing systemic autoimmune disease: development and validation of a real-time risk model. Front Immunol, 2024, 15: 1384229. doi: 10.3389/fimmu.2024. 1384229.
ANDRADE L E C, KLOTZ W, HEROLD M, et al. Reflecting on a decade f the international consensus on ANA patterns (ICAP): Accomplishments and challenges from the perspective of the 7th ICAP workshop. Autoimmun Rev, 2024, 23(9): 103608. doi: 10.1016/j.autrev. 2024.103608.
CASIANO C A, HUMBEL R L, PEEBLES C, et al. Autoimmunity to the cell cycle-dependent centromere protein p330d/CENP-F in disorders associated with cell proliferation. J Autoimmun, 1995, 8(4): 575-586. doi: 10.1016/0896-8411(95)90009-8.
CASIANO C A, LANDBERG G, OCHS R L, et al. Autoantibodies to a novel cell cycle-regulated protein that accumulates in the nuclear matrix during S phase and is localized in the kinetochores and spindle midzone during mitosis. J Cell Sci, 1993, 106(Pt 4): 1045-1056. doi: 10.1242/jcs.106.4.1045.
Al-MUGHALES J A. Anti-nuclear antibodies patterns in patients with systemic lupus erythematosus and their correlation with other diagnostic immunological parameters. Front Immunol, 2022, 13: 850759. doi: 10. 3389/fimmu.2022.850759.
Von MÜHLEN C A, GARCIA-De La TORRE I, INFANTINO M, et al. How to report the antinuclear antibodies (anti-cell antibodies) test on HEp-2 cells: guidelines from ICAP initiative. Immunol Res, 2021, 69(6): 594-608. doi: 10.1007/s12026-021-09233-0.
ZOU H Y, CHAO Y N, BAI W D, et al. Expression of antinuclear antibody and clinical manifestataion in patients with systemic lupus erythematosus. Journal of Chengdu Medical College, 2021, 16(5): 591-594. doi: 10.3969/j.issn.1674-2257.2021.05.010.
RATTNER J B, REES J, WHITEHEAD C M, et al. High frequency of neoplasia in patients with autoantibodies to centromere protein CENP-F. Clin Invest Med, 1997, 20(5): 308-319.
BONACI-NIKOLIC B, ANDREJEVIC S, BUKILICA M, et al. Autoantibodies to mitotic apparatus: association with other autoantibodies and their clinical significance. J Clin Immunol, 2006, 26(5): 438-446. doi: 10.1007/s10875-006-9038-y.
FRITZLER M J, RATTNER J B, LUFT L A M, et al. Historical perspectives on the discovery and elucidation of autoantibodies to centromere proteins (CENP) and the emerging importance of antibodies to CENP-F. Autoimmun Rev, 2011, 10(4): 194-200. doi: 10.1016/j.autrev. 2010.09.025.
VERMEERSCH P, BOSSUYT X. Prevalence and clinical significance of rare antinuclear antibody patterns. Autoimmun Rev, 2013, 12(10): 998-1003. doi: 10.1016/j.autrev.2013.03.014.
Refbacks
- There are currently no refbacks.
